GlaxoSmithKline Pakistan Ltd. Financial Results for the period ended June 30, 2017.
The company’s Net Sales for the period declined by 158% percent in the outgoing year, whereas the Profit after Taxation for the Period went from loss in the previous years to 307.4 billion in the outgoing year.
The board has recommended no cash dividend, bonus shares or right shares.
Comparison of Key Financials:
|
Financial Results – For Period Ended |
|||
|
Key Financials |
June 30, 2017 |
June 30, 2016 |
% Change |
|
Net Sales |
3,746,461,774 |
1,452,239,805 |
158% |
|
Cost of Sales |
2,244,996,000 |
1,423,435,439 |
58% |
|
Gross Profit |
1,501,465,774 |
28,804,366 |
5113% |
|
Selling, Marketing and distribution Expenses |
870,515,596 |
289,849,111 |
200% |
|
Administrative Expenses |
107,357,766 |
40,412,410 |
166% |
|
Other Operating Expenses |
51,859,553 |
14,097,824 |
268% |
|
Other Income |
120,310,986 |
4,363,507 |
2657% |
|
Operating Profit/(loss) |
592,043,845 |
(311,191,472) |
|
|
Financial Charges |
154,139 |
70,626 |
118% |
|
Profit/(loss) before taxation |
591,889,706 |
(311,262,098) |
|
|
Taxation |
284,391,254 |
90,945,361 |
213% |
|
Profit/(loss) after taxation |
307,498,452 |
(402,207,459) |
|
|
EPS – Profit/(loss) per share |
3.22 |
(8.42) |
|
Rupees in Thousands
The complete statements can be accessed here.
